With a strategic emphasis on oncology, we have built a global pipeline through collaborations and internal discoveries with more than 10 drug candidates in development, including small molecules, monoclonal/bifunctional antibodies and oncolytic virus.
Currently, we have three programs that are being investigated in clinical trials:
An FDA Fast Track-designated treatment AN2025 (Buparlisib) for head and neck squamous cell carcinoma (HNSCC) in a global phase III clinical trial;
An oral EP4 antagonist AN0025 (Palupiprant) is in early-stage clinical development in multiple tumor types in combination with other treatment options including chemo-radiation and anti‑PD‑(L)1 therapies;
A FDA Fast Track-designated intravenously-administered oncolytic virus AN1004 (Pelareorep) to have completed a phase II clinical trial.
We have also accumulated a number of preclinical drug candidates, including AN4005 (an oral PD-L1 inhibitor), AN6025 (HPK1 inhibitor) and AN3025 (TNFR2).
We are working on discovering combination solutions while developing unique 'cocktail therapy', aiming to bring effective treatment for patients.